Abstract: Procedure for the detection of bitter almonds based on the processing of digital images, and a system and device associated therewith. Detection procedure and system for the automated classification of sweet and bitter almonds based on the processing of digital images. The fluorescence of the cyanogenic compounds naturally present in almonds generates a clear difference in colour between sweet and bitter almonds which subsequently is analysed and classified by means of a computer program. The invention also includes the device, either portable or automatic, for carrying out the classification of bitter or sweet almonds. This device will be necessary during the goods reception process and in the validation/verification of the quality of the finished product, prior to the loading and transport process.

Abstract: The invention relates to a computer program that when executed on a computer causes a system to execute a method, particularly a computer-implemented method for determining a plurality of functional ocular parameters, with the system comprising an optical system (3) with a display system (4) that is configured to independently project a visual stimulus to a left and a right eye of a test person, an eye-tracking system (5) configured to record a gaze direction (100) and a pupil size (102) of the left as well as the right eye, said computer (2) being configured to control the optical system (3) and to receive recorded data from the eye-tracking system (5), wherein an afferent pupillary defect (APD), particularly a relative afferent pupillary defect (RAPD) is determined from a first trial session consisting of a sequence of first kind of stimuli presented to the left and the right eye of the test person eyes with the display system (4), and wherein a visual field (400) is determined from a second trial session c

Abstract: The invention relates to an aluminum secondary battery comprising at least one positive electrode, at least one negative electrode, at least one electrolyte, and at least one additive, the electrolyte comprising at least one room temperature ionic liquid (RTIL), made of at least one organic salt and at least one first aluminum salt, and/or at least one deep eutectic solvent (DES) made of at least one organic solvent and at least one first aluminum salt, the additive containing bivalent metal cations and/or being suitable for forming bivalent metal cations.

Abstract: The present invention relates to an anti-CD47 antibody or an antigen-binding fragment thereof, comprising variable heavy chain complementarity determining regions 1 to 3 (CDRH1, CDRH2, CDRH3) and variable light chain complementarity determining regions 1 to 3 (CDRL1, CDRL2, CDRL3). The anti-CD47 antibody or an antigen-binding fragment thereof is capable of blocking the interaction of CD47 with signal regulatory protein alpha (SIRPalpha). Further envisaged is an anti-CD47 antibody or antigen-binding fragment combined to a further functional component.

Abstract: Methods for processing a crude oil feedstock include introducing a crude oil stream to a reactive distillation unit to remove conradson carbon and metals from the crude oil stream and generate a distillate stream having a mean boiling point distribution less than the crude oil stream and passing the distillate stream in a gaseous form in a continuous manner and without further processing to a catalytic cracking reactor that cracks the distillate stream to form a petrochemical product stream including light olefins and BTX. The catalytic cracking reactor includes a cracking catalyst and a susceptor material dispersed throughout the catalytic cracking reactor. Further, the catalytic cracking reactor operates at a temperature of 300° C. to 800° C. with heating from magnetic induction of the susceptor material.

Abstract: Methods for processing a crude oil feedstock include introducing a crude oil stream to a reactive distillation unit to remove conradson carbon and metals from the crude oil stream and generate a distillate stream having a mean boiling point distribution less than the crude oil stream and passing the distillate stream in a gaseous form in a continuous manner and without further processing to a catalytic cracking reactor operating at a temperature of 300° C. to 800° C. with a cracking catalyst disposed therein that cracks the distillate stream to form a petrochemical product stream including light olefins and BTX.

Abstract: The invention relates to a radial blood pump (1) for supporting a blood flow (106) in a human or animal heart (205) comprising a first and a second inlet channel (41, 42), a first outlet channel (51, 52), a first electric motor (71) comprising a first stator (77) and a first internal rotor (75), wherein the first electric motor (71) is configured to drive an impeller (2, 2a, 2b) arranged at an intersection of the first with the second inlet channel (41, 42), wherein the impeller (2, 2a, 2b) is connected to the first internal rotor (75) and wherein the impeller (2, 2a, 2b) comprises a merging portion (22) arranged at the intersection, where a merging of a first blood flow (106) coming from the first inlet channel (41) and a second blood flow (107) coming from the second inlet channel (42) takes place, wherein the impeller (2, 2a, 2b) is configured to pump the first and second blood flow (106, 107) from the first and second inlet channel (41, 42) via the merging portion (22) to the first outlet channel (51), a

Abstract: An aspect of the invention provides a method and a product for determining a modification of the therapy management by using a processor unit which retrieves few data related to the blood glucose measurement performed over a predetermined time period; retrieve the medication delivery parameter executed by the delivery device over said predetermined time period; retrieve from the memory data associated to the CIR of the patient; and determine a modification to the therapy based on at least a part of the retrieved data.

Abstract: The present invention provides an isolated protein exhibiting an antiaggregating activity and/or disaggregating activity toward a target protein comprising an extended polyQ stretch. The protein comprises a Zn2+-binding region, wherein the conserved motif is HxxEHx75-80E and x is any amino acid. The nucleic acid construct encoding said protein as well as the corresponding mRNA sequence are also provided. The protein, the nucleic acid construct or mRNA sequence are for use in a method for prevention or treatment of a neurodegenerative disease that is caused by aggregates comprising at least one target protein and/or by the mRNA encoding for said target protein, wherein the target protein causes e.g. Huntington's disease or Machado-Joseph disease.

Abstract: A method (500) for conditioning or hydrolysis of an extruded membrane is disclosed. The method (500) comprising ion exchange processes in divided electrochemical cells using a cation exchanger membrane. The method (500) includes extruding the perfluorosulfonyl fluoride membranes from perfluorosulfonyl fluoride granulate. The method (500) also includes using a pretreatment technique to increase the ionic conductivity of the extruded perfluorosulfonyl fluoride membranes before using the perfluorosulfonic acid membranes in electrolysis cells. The method (500) also includes applying a milder pretreatment technique by activating S—F bonds to execute nucleophilic exchange of the fluoride group in a reaction. The method (500) also includes hydrolyzing sulfonyl fluoride groups to sulfonic acid using triethylsilanol.

Abstract: The present invention relates to a pharmaceutical nucleic acid agent capable of downregulating or inhibiting the activity of the minor spliceosome (MiS) for use in treatment or prevention of recurrence of cancer. The invention also relates to a method for the diagnosis of cancer.

Abstract: The disclosure relates to the field of multiple sclerosis (MS) stratification by analyzing the body fluid of an MS patient. The invention also relates to the field of antigen specific immunotherapies, such as the induction of tolerance.

Abstract: Therapeutic compounds of the invention comprise peptidomimetics, including those of formula (I), which has been prepared using solid-phase peptide synthesis. It is useful in the treatment of a cancer, including, for the treatment of a pancreatic cancer, a lung cancer or a colorectal cancer, further, including, a treatment for a pancreatic ductal adenocarcinoma.

Abstract: A ligand regulated protein-protein interaction system based on a lipocalin-fold molecule including: (a) a lipocalin-fold molecule; (b) a lipocalin-fold ligand with a low molecular weight of 1500 Da or below; and (c) a lipocalin-fold binding interaction partner, wherein the lipocalin-fold molecule can bind to the lipocalin-fold ligand; and wherein the lipocalin-fold molecule bound to the lipocalin-fold ligand binds to the lipocalin-fold binding interaction partner with an affinity which is at least 10-fold higher than the affinity of the lipocalin-fold molecule not bound to the lipocalin-fold ligand; and wherein the lipocalin-fold binding interaction partner is not a naturally occurring protein which has an affinity of <10 ?M to any naturally occurring lipocalin-fold molecule in the presence of any lipocalin-fold ligand.

Abstract: The present invention provides a pharmaceutical composition for use in prevention or treatment of a human rhinovirus (HRV) infection. The composition comprises an aldohexose, wherein the hydroxyl group at carbon 2 of the aldohexose is replaced by any one of H, F, Cl, Br, I, SH, Me, OMe and SMe, such as a 2-deoxy-glucose. Furthermore, a dispenser for intranasal administration, such as a nasal spray or nose drop applicator containing said pharmaceutical composition is provided. In addition, an inhalation device, such as a metered-dose inhaler, a dry-powder inhaler or a nebuliser, comprising said composition is provided.

Abstract: The invention relates to a computer program causing a system with a computer to execute a method, particularly a computer-implemented method for determining at least one functional ocular parameter, namely a visual acuity, wherein the system comprises an optical system with a display system that is configured to independently project a visual stimulus to a left and a right eye of a test person, wherein the visual stimulus comprises a plurality of patches arranged on a background, an eye-tracking system configured to record a gaze direction of the left as well as the right eye, a computer configured to control the optical system and to receive recorded data from the eye-tracking system, the method comprising at least the steps of: executing a trial session for determining the visual acuity, wherein the trial session comprises a plurality of the visual stimuli that are presented, with the optical system to the left and/or the right eye of the test person; recording data during the trial session comprising infor

Abstract: The present invention provides a pharmaceutical composition for use in prevention or treatment of a human rhinovirus (HRV) infection. The composition comprises an aldohexose, wherein the hydroxyl group at carbon 2 of the aldohexose is replaced by any one of H, F, Cl, Br, I, SH, Me, OMe and SMe, such as a 2-deoxy-glucose. Furthermore, a dispenser for intranasal administration, such as a nasal spray or nose drop applicator containing said pharmaceutical composition is provided. In addition, an inhalation device, such as a metered-dose inhaler, a dry-powder inhaler or a nebuliser, comprising said composition is provided.

Abstract: Polyether polymers represented by the following formula [I]: —(CH2CHR—O—)m—??(I) wherein 10 to 90% of the residues R are hydrogen and 10% to 90% of the residues R are independently from each other selected from the group made of, methoxymethyl, ethoxymethyl, n-propoxymethyl and iso-propoxymethyl; 1 to 100% of the residues R are methoxymethyl; up to 50% of the residues R may be selected from the group made of ethoxymethyl, n-propoxymethyl and iso-propoxymethyl; and m is in the range of from 10 to 1000 and the dispersity is 1.15 or less. A process for their preparation, conjugates thereof and the use thereof.

Abstract: The invention relates to a device, a method, and a kit for separating particles of different sizes in a liquid. The invention additionally relates to applications of the device. The device and the method involve the capability of binding particles to solid phase particles with different diameters in a liquid, whereby the hydrodynamic diameter of the solid-phase particles determines whether the particles can pass through pores of a filter element, the diameter of said pores being modifiable in a controlled manner (e.g., the diameter can be increased or decreased). Thus, particles of equal size (e.g., B-cells and T-cells) of a liquid can be separated from one another with a high degree of separation efficiency, wherein the particles can be separated simply, quickly, and inexpensively. High yields can be produced, and the particles can be provided in a therapeutically applicable liquid.

Abstract: Provided herein is a method for treating a lymphoma in a subject in need thereof, comprising administering to the subject an effective amount of at least one PD-1 pathway agonist.